Trellis Bioscience Inc.

Our human mAb TRL1068 disrupts bacterial biofilm and makes traditional antibiotics work again overcoming drug resistance

Add To Watchlist
General Information
Company Name
Trellis Bioscience Inc.
Founded Year
1998
Location (Offices)
Redwood City, United States +1
Founders / Decision Makers
Stote Ellsworth - Chief Technology Officer Stefan Ryser - President & Chief Executive Officer Lawrence Kauvar - Founder & Senior Vice President Anton Leighton - Chief Medical Officer
Number of Employees
18
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Grant
Social Media

Trellis Bioscience Inc. - Company Profile

Trellis Bioscience is a biotechnology startup pioneering cellular informatics to enhance and quantify therapeutic antibody treatments on a single cell level. The company, founded in 1998, offers a technology platform focused on cellular informatics, with a cell biology platform that provides a direct readout at the single cell level. This platform is pivotal in the discovery and production of therapeutic monoclonal antibodies. Trellis Bioscience's innovative technology allows for monitoring the activity of diverse cell types and quantifying the impact of potential therapeutic interventions. Based in San Francisco, California, the company received a $3.20M grant investment on 01 October 2019 from CARB-X. With its focus on precision medicine and cutting-edge technology, Trellis Bioscience is positioned to make significant contributions to the biotechnology and healthcare industries. This recent investment is a testament to the potential and value of the company's unique approach to cellular informatics.

Taxonomy: cellular informatics, therapeutic antibody treatments, technology platform, monoclonal antibodies, cell biology platform, single cell level, cell types monitoring, therapeutic interventions, San Francisco, discovery platform

Funding Rounds & Investors of Trellis Bioscience Inc. (5)

View All
Funding Stage Amount No. Investors Investors Date
Grant $3.20M 1
CARB-X, investor in Trellis Bioscience Inc.'s Grant round
01 Oct 2019
Debt Financing $235.00K - 09 Nov 2011
Venture Round $11.72M - 07 Aug 2009
Series B $10.00M 4
Easton Capital, investor in Trellis Bioscience Inc.'s Series B round Novartis Venture Fund, investor in Trellis Bioscience Inc.'s Series B round Morgenthaler Ventures, investor in Trellis Bioscience Inc.'s Series B round Pac-Link, investor in Trellis Bioscience Inc.'s Series B round
14 Feb 2007
Series A $3.43M - 02 Jan 2004

Latest News of Trellis Bioscience Inc.

View All

No recent news or press coverage available for Trellis Bioscience Inc..

Similar Companies to Trellis Bioscience Inc.

View All
Immunome, Inc. - Similar company to Trellis Bioscience Inc.
Immunome, Inc. Developing antibody-based therapeutics by unlocking the human memory B cell response.
ExeVir - Similar company to Trellis Bioscience Inc.
ExeVir Rapid Viral control in a world that needs it
Pure MHC, LLC - Similar company to Trellis Bioscience Inc.
Pure MHC, LLC Our Mission is to create a novel class of therapeutics for the treatment of cancer and infectious diseases.
RevOpsis Therapeutics - Similar company to Trellis Bioscience Inc.
RevOpsis Therapeutics Harnessing a new era of multispecific biologics to discover ​ and develop breakthrough treatments
Design Pharmaceuticals Inc. - Similar company to Trellis Bioscience Inc.
Design Pharmaceuticals Inc. Boundless GPCR drug discovery
Circle Decoration Circle Decoration

Want to dive deeper into Trellis Bioscience Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now